Ignite Creation Date:
2025-12-24 @ 3:40 PM
Ignite Modification Date:
2026-01-01 @ 7:24 PM
Study NCT ID:
NCT00636792
Status:
COMPLETED
Last Update Posted:
2012-01-13
First Post:
2008-03-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
Sponsor:
Millennium Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-02
Start Date Type:
None
Primary Completion Date:
2010-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2010-05
Completion Date Type:
ACTUAL
First Submit Date:
2008-03-11
First Submit QC Date:
None
Study First Post Date:
2008-03-14
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2011-05-31
Results First Submit QC Date:
None
Results First Post Date:
2011-06-22
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2012-01-11
Last Update Post Date:
2012-01-13
Last Update Post Date Type:
ESTIMATED